MSB Trading - 2020, page-12365

ROFL .... Here's just one example ....you are simply demonstrating you are nothing more than a clown taking the pi$$ ... I am sure the children and their parents suffering aGVHD would disagree strongly with you

Melbourne, Australia; February 24, 2020; and New York, USA; February 23, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that aggregated results from 309 children treated with Ryoncil™ (remestemcel-L) were presented at the American Society for Transplantation Cellular Therapy and the Center for International Blood & Bone Marrow Transplant Research (TCT) meeting in Orlando, Florida on February 22. The data showed that treatment with RYONCIL across three separate trials resulted in consistent treatment responses and survival outcomes in children with steroid-refractory acute graft versus host disease (SR-aGVHD).


Key findings and conclusions were:

• Consistent safety and efficacy were observed across the continuum from first-line treatment after steroid failure through the most challenging patients who received RYONCIL as salvage after exhausting all other options.

• In the aggregated dataset, 204 of the 309 (66%) patients achieved an overall response at Day 28 following a four-week course of RYONCIL.

• Results were consistent across all grades of disease, including most severe (IBMTR Grade C/D or Glucksberg Grade 3/4).

• In the most severe patients (Grade C/D), who accounted for 82% of all treated patients, Day 28 overall response was 65%.

• Overall response at Day 28 was strongly predictive of survival at Day 100 and Day 180.

• Overall response at Day 28 was strongly predictive of survival at Day 100 and Day 180.

• Day 28 responders were more than twice as likely to survive as non-responders (84% vs 39% at Day 100, and 83% vs 38% at Day 180).

• RYONCIL was well tolerated with no infusion-related toxicity and no identified safety concerns